ADMA Biologics, Inc. (NASDAQ:ADMA) Short Interest Update

ADMA Biologics, Inc. (NASDAQ:ADMA) was the recipient of a large growth in short interest during the month of January. As of January 15th, there was short interest totalling 13,620,000 shares, a growth of 11.8% from the December 31st total of 12,180,000 shares. Based on an average daily trading volume, of 3,500,000 shares, the short-interest ratio is currently 3.9 days.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the stock. HC Wainwright raised their price objective on shares of ADMA Biologics from $18.00 to $26.00 and gave the company a “buy” rating in a research note on Friday, November 8th. Raymond James raised their target price on shares of ADMA Biologics from $18.00 to $25.00 and gave the company a “strong-buy” rating in a report on Friday, November 8th.

ADMA Biologics Stock Performance

NASDAQ:ADMA opened at $16.15 on Monday. The company has a market capitalization of $3.82 billion, a P/E ratio of 57.68 and a beta of 0.76. ADMA Biologics has a twelve month low of $5.02 and a twelve month high of $23.64. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48. The firm has a 50-day moving average price of $18.10 and a two-hundred day moving average price of $17.61.

ADMA Biologics (NASDAQ:ADMA) last issued its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.15 EPS for the quarter, topping analysts’ consensus estimates of $0.13 by $0.02. The business had revenue of $119.84 million during the quarter, compared to the consensus estimate of $107.25 million. ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. During the same period in the previous year, the firm posted $0.01 earnings per share. As a group, research analysts expect that ADMA Biologics will post 0.51 earnings per share for the current fiscal year.

Insider Activity at ADMA Biologics

In related news, CFO Brad L. Tade sold 15,000 shares of the stock in a transaction on Friday, November 22nd. The shares were sold at an average price of $21.15, for a total value of $317,250.00. Following the transaction, the chief financial officer now directly owns 199,433 shares of the company’s stock, valued at $4,218,007.95. This trade represents a 7.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 3.70% of the company’s stock.

Institutional Investors Weigh In On ADMA Biologics

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Marshall Wace LLP grew its holdings in ADMA Biologics by 44.1% in the second quarter. Marshall Wace LLP now owns 26,800 shares of the biotechnology company’s stock valued at $300,000 after purchasing an additional 8,203 shares during the period. The Manufacturers Life Insurance Company grew its holdings in ADMA Biologics by 17.1% in the second quarter. The Manufacturers Life Insurance Company now owns 129,739 shares of the biotechnology company’s stock valued at $1,450,000 after purchasing an additional 18,977 shares during the period. Algert Global LLC lifted its position in ADMA Biologics by 831.6% during the second quarter. Algert Global LLC now owns 118,290 shares of the biotechnology company’s stock valued at $1,322,000 after buying an additional 105,593 shares in the last quarter. Creative Planning lifted its position in ADMA Biologics by 73.9% during the second quarter. Creative Planning now owns 36,147 shares of the biotechnology company’s stock valued at $404,000 after buying an additional 15,363 shares in the last quarter. Finally, Point72 Asset Management L.P. acquired a new position in ADMA Biologics during the second quarter valued at approximately $1,157,000. 75.68% of the stock is currently owned by hedge funds and other institutional investors.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.